Generated by AI
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, especially patients whose current lipid-lowering treatments are not adequately effective or well tolerated. The company’s lead program centers on obicetrapib, a low-dose oral CETP inhibitor being studied as a monotherapy and in combination with ezetimibe to help lower LDL cholesterol in cardiovascular settings. NewAmsterdam Pharma also works on broader applications for cardiometabolic care, reflecting its emphasis on non-statin medicine and patient-friendly treatment options. Headquartered in Naarden, the Netherlands, NewAmsterdam Pharma Company N.V. serves the biotechnology and pharmaceuticals market by advancing drug candidates aimed at addressing unmet needs in long-term cardiovascular risk management.
WebsiteGooimeer 2-35
Naarden, 1411 DC
Netherlands
The latest articles about NAMS.
Summary of Sep 4's posts. Generated by AI.
No summary yet.
Summary of Dec 10's posts. Generated by AI.
No summary yet.
Summary of Jun 9's posts. Generated by AI.
Investors talking about NAMS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.